Medomeksi - Instructions For Use, Price, Reviews, Analogues

2024 Author: Rachel Wainwright | [email protected]. Last modified: 2023-12-15 07:39

Medomeksi

Medomeksi: instructions for use and reviews

1. 1. Release form and composition
2. 2. Pharmacological properties
3. 3. Indications for use
4. 4. Contraindications
5. 5. Method of application and dosage
6. 6. Side effects
7. 7. Overdose
8. 8. Special instructions
9. 9. Application during pregnancy and lactation
10. 10. Use in childhood
11. 11. In case of impaired renal function
12. 12. For violations of liver function
13. 13. Drug interactions
14. 14. Analogs
15. 15. Terms and conditions of storage
16. 16. Terms of dispensing from pharmacies
17. 17. Reviews
18. 18. Price in pharmacies

Latin name: Medomexi

ATX code: N07XX

Active ingredient: ethylmethylhydroxypyridine succinate (ethylmethylhydroxypyridine succinate)

Manufacturer: PJSC "Biochemist" (Russia), FSUE "Moscow Endocrine Plant" (Russia), LLC "Ozon" (Russia)

Description and photo update: 2018-21-11

Prices in pharmacies: from 109 rubles.

Buy

Medomeksi is an antioxidant drug.

Release form and composition

Dosage forms of Medomeksi:

• film-coated tablets: almost white or white, biconvex, cylindrical, without dividing lines, the core is white with a cream shade or white (10 or 30 pcs. in blisters, in a cardboard box 1, 2, 3, 4, 5 or 10 packages; 10, 20, 30, 40, 50 or 100 pcs. In polymer containers, in a cardboard box 1 container);
• solution for intravenous (i / v) and intramuscular (i / m) administration: clear liquid, colorless or yellowish (2 ml or 5 ml in glass ampoules, 5 ampoules in blisters, in a cardboard box 1, 2, 20, 50 or 100 packs).

1 tablet contains:

• active substance: ethylmethylhydroxypyridine succinate - 125 mg;
• auxiliary components: microcrystalline cellulose, milk sugar (lactose monohydrate), potato starch, povidone (polyvinylpyrrolidone), magnesium stearate, croscarmellose sodium;
• composition of the film shell: macrogol, hypromellose, titanium dioxide.

1 ml of solution contains:

• active substance: ethylmethylhydroxypyridine succinate - 50 mg;
• auxiliary components: sodium metabisulfite (sodium disulfite), water for injection.

Pharmacological properties

Pharmacodynamics

Medomeksi is an antioxidant drug that improves the metabolism of brain tissues, their blood supply, rheological properties and blood microcirculation, and decreases platelet aggregation. Ethylmethylhydroxypyridine succinate has the property of stabilizing the membrane structures of platelets and erythrocytes. Its hypolipidemic effect reduces the concentration of low density lipoproteins and total cholesterol in the blood.

In addition to the antioxidant drug, it has a membrane-protective effect. Inhibits lipid peroxidation, stabilizes blood cell membranes, increases the activity of the enzyme superoxide dismutase and the ratio of lipids and proteins in the cell membrane. Increases blood flow, decreasing its viscosity. Medomexi is able to modulate the activity of membrane-bound enzymes (adenylate cyclase, calcium-independent phosphodiesterase, acetylcholinesterase), receptor complexes [GABA (gamma-aminobutyric acid), benzodiazepine, acetylcholine], causing an increase in their ability to bind to ligands. Improves synaptic transmission, is active for maintaining the structural and functional organization of biomembranes and transport of neurotransmitters. Promotes an increase in the content of dopamine in the brain. Under conditions of hypoxia, it enhances the compensatory activation of aerobic glycolysis, causes a decrease in the degree of inhibition of oxidative processes in the Krebs cycle, increases the content of creatine phosphate and ATP (adenosine triphosphoric acid), activates the energy-synthesizing functions of mitochondria, and stabilizes cell membranes.

The pharmacological activity of Medomeksi allows its use to increase the body's resistance to stress, provide anxiolytic action, which is not accompanied by drowsiness and muscle relaxant effect, improve memory, concentration of attention and mental activity, facilitate learning. The drug has an anticonvulsant effect, exhibits antioxidant and antihypoxic properties, improves performance, weakens the toxic effect of alcohol.

Pharmacokinetics

When taken orally, Medomeksi is rapidly absorbed, the half-absorption period lasts about 1 hour.

Regardless of the dosage form of the drug ethylmethylhydroxypyridine, succinate is rapidly distributed in tissues and organs. The maximum concentration (C _max) of the drug in the blood plasma is achieved when taking tablets after 0.5 hours and is 0.05–0.1 μg / ml, with i / m administration, its level corresponds to 2.5–4 μg / ml after 0, 3–0.58 hours after injection of 400–500 mg of Medomeksi solution.

In the liver, ethylmethylhydroxypyridine succinate is metabolized by glucuronidation with the formation of metabolites: 3-hydroxypyridine phosphate (formed in the liver and with the participation of alkaline phosphatase decomposes into 3-hydroxypyridine and phosphoric acid), two glucuronconjugates, a pharmacologically active metabolite in large quantities, which is found later 1-2 days after using the drug, and a metabolite, which is excreted in large quantities in the urine.

When taking tablets, the half-life (T _1/2) of the active substance is about 5 hours.

With intramuscular injection, T _1/2 and the average retention time of the drug in the body is 0.7-1.3 hours.

Within 12 hours, 50% of the dose taken is rapidly excreted through the kidneys in the form of metabolites, 0.3% unchanged. The most intense elimination of the drug occurs within the first four hours after taking it. Indicators of metabolites and unchanged ethylmethylhydroxypyridine succinate in urine have individual variability.

Indications for use

• vegetative vascular dystonia;
• neurosis-like and neurotic states, accompanied by anxiety disorders;
• encephalopathy;
• mild form of cognitive impairment of atherosclerotic (vascular) genesis;
• complex therapy of acute disorders of cerebral circulation by ischemic type;
• withdrawal syndrome with a predominance of vegetative-vascular and neurosis-like disorders in alcoholism;
• acute intoxication caused by taking antipsychotic drugs (in oral form - as part of combination therapy).

Additionally for Medomeksi solution:

• age-related decline in cognitive functions (disorders of concentration, memory, orientation) in elderly patients;
• asthenic conditions caused by exposure to extreme (stress-situation) factors.

Contraindications

• acute liver failure;
• acute renal failure;
• childhood;
• period of pregnancy;
• breast-feeding;
• individual intolerance to the components of Medomeksi.

In addition, the use of tablets is contraindicated for lactose intolerance, lactase deficiency, glucose-galactose malabsorption syndrome.

It is recommended to use Medomeksi solution with caution if there is a history of allergic diseases.

Instructions for the use of Medomeksi: method and dosage

Film-coated tablets

Medomeksi tablets are taken orally.

Recommended dosage: initial dose - 1-2 pcs. (125-250 mg) 1-2 times a day. In order to achieve the desired therapeutic effect, a gradual increase in the dose is shown (125–250 mg 3 times a day). The maximum daily dose is 6 pcs. (750 mg). The duration of the course of treatment is 14–42 days.

As part of the complex therapy of withdrawal symptoms, it is recommended to use 250-500 mg 3 times a day. Taking Medomeksi is stopped gradually, reducing the daily dose for 2-3 days.

Solution for i / v and i / m administration

Medomeksi solution is used by i / m and jet or drip i / v administration.

When prescribing the drug intravenously, the injection procedure should be continued for at least 5-7 minutes. The drip rate should be 40-60 drops per minute. To prepare the infusion solution, use a 0.9% sodium chloride solution.

The dose should be selected individually, taking into account the clinical indications and the patient's condition.

It is recommended to start treatment with a dose of 50-100 mg 1-3 times a day. With good tolerance, the dose is gradually increased to therapeutically effective. The maximum daily dose is 800 mg.

Recommended dosage of Medomeksi:

• vegetative-vascular dystonia, asthenic, neurotic and neurosis-like states: intramuscularly at a dose of 50–400 mg per day for 14 days;
• dyscirculatory encephalopathy in the decompensation phase: 100 mg 2-3 times a day for 14 days intravenous stream or drip, the next 14 days - intramuscularly;
• prevention of discirculatory encephalopathy: i / m, 100 mg 2 times a day for 10-14 days;
• mild cognitive impairment, age-related decline in cognitive functions, anxiety disorders: i / m, 100–300 mg per day for 14–30 days;
• acute disorders of cerebral circulation (as part of complex therapy): intravenous drip of 200-300 mg once a day for the first 2-4 days, then 100 mg intramuscularly 3 times a day. Duration of the course - 10-14 days;
• alcohol withdrawal syndrome: i / m, 100-200 mg 2-3 times a day, or i / v drip, 100-200 mg 1-2 times a day. The duration of the course is 5–7 days;
• acute intoxication with antipsychotic drugs: intravenous stream or drip in a daily dose of 50-300 mg. The course of treatment is 7-14 days.

Side effects

Film-coated tablets

• from the digestive system: diarrhea, dryness of the oral mucosa, nausea;
• others: drowsiness, allergic reactions.

Solution for i / v and i / m administration

• from the digestive system: with prolonged therapy - flatulence, nausea;
• from the central nervous system: drowsiness, sleep disturbance;
• others: against the background of intravenous injection (more often with jet injection): a feeling of "spreading" heat throughout the body, dryness of the mucous membrane of the mouth, metal taste in the mouth, sore throat, unpleasant odor, chest discomfort, at a high injection rate - short-term lack of air.

Overdose

Symptoms: Sleep disturbance such as insomnia or drowsiness. In addition, in case of an overdose that occurs with intravenous administration, there is a slight increase in blood pressure (BP) during the first 1.5-2 hours.

Treatment: symptomatic therapy. With a significant increase in blood pressure, the appointment of taking antihypertensive drugs under the control of blood pressure is indicated, with severe insomnia - the use of hypnotics. With a mild overdose, treatment is usually not required, the condition returns to normal within 24 hours on its own.

special instructions

Influence on the ability to drive vehicles and complex mechanisms

During the period of using Medomeksi, care must be taken when engaging in potentially hazardous activities, including driving vehicles and mechanisms.

Application during pregnancy and lactation

The appointment of Medomeksi is contraindicated during the gestation period and during breastfeeding.

Pediatric use

Due to the lack of sufficient information on the safety and efficacy of using Medomeksi in childhood, it is contraindicated to prescribe the drug for the treatment of this category of patients.

With impaired renal function

The appointment of Medomeksi is contraindicated in acute renal failure.

For violations of liver function

According to the instructions, Medomeksi is contraindicated in acute liver failure.

Drug interactions

With the simultaneous use of Medomeksi:

• psychotropic drugs retain their properties and do not cause a violation of the pharmacological properties of the drug;
• anxiolytics of the benzodiazepine series, antiparkinsonian (including levodopa), antiepileptic (carbamazepine) drugs increase their therapeutic activity;
• nitrates enhance their effect.

Analogs

Medomeksi analogs are: Meksidant, Meksikor, Metostabil, Meksidol, Meksifin, Meksibel, Meksiprim, Cerecard, Neuroks.

Terms and conditions of storage

Keep out of the reach of children.

Store at temperatures up to 25 ° C in a dark place, tablets in a dry place.

The shelf life is 3 years.

Terms of dispensing from pharmacies

Dispensed by prescription.

Reviews about Medomexi

The few reviews about Medomeksi are positive. The drug rarely causes the development of undesirable effects, while their symptoms disappear on their own during treatment.

Price for Medomeksi in pharmacies

The price of Medomeksi for a package containing 10 ampoules of 2 ml solution can range from 440 rubles.

Medomeksi: prices in online pharmacies

Drug name Price Pharmacy

Medomeksi (for injection) 50 mg / ml solution for intravenous and intramuscular administration 2 ml 10 pcs. 109 RUB Buy

Medomeksi (for injection) 50 mg / ml solution for intravenous and intramuscular administration 5 ml 5 pcs. RUB 111 Buy

Medomeksi solution for intravenous and intramuscular injection. 50mg / ml 2ml 10 pcs. 116 RUB Buy

Medomeksi 125 mg film-coated tablets 30 pcs. 175 RUB Buy

Anna Kozlova Medical journalist About the author

Education: Rostov State Medical University, specialty "General Medicine".

Information about the drug is generalized, provided for informational purposes only and does not replace the official instructions. Self-medication is hazardous to health!